Transgene to Present TG4050 Vaccine Data at World Vaccine Congress

Transgene, a biotech company specializing in virus-based immunotherapies for cancer, will present findings on TG4050 at the World Vaccine Congress in Washington, D.C., from March 31 to April 2, 2026. The 30-minute oral presentation, scheduled for April 1st, will focus on TG4050, an Individualized Neoantigen Therapeutic Vaccine (INTV).

The presentation will cover Phase 1 trial results in head and neck cancer, showing patients treated with TG4050 developed immune responses targeting tumor neoantigens, remaining tumor-free two years post-treatment. The data supports the ongoing Phase 2 trial and suggests potential applications in other solid tumors with unmet medical needs.

Dr. Katell Bidet Huang, Head of Translational Medicine at Transgene, emphasizes the innovative nature of TG4050, powered by AI, as it is tailored to each patient's tumor characteristics. The company aims to prevent cancer relapse using their myvac® platform, continuing data generation in additional cancer indications.